KR20120100978A - 조합물 - Google Patents

조합물 Download PDF

Info

Publication number
KR20120100978A
KR20120100978A KR1020127011758A KR20127011758A KR20120100978A KR 20120100978 A KR20120100978 A KR 20120100978A KR 1020127011758 A KR1020127011758 A KR 1020127011758A KR 20127011758 A KR20127011758 A KR 20127011758A KR 20120100978 A KR20120100978 A KR 20120100978A
Authority
KR
South Korea
Prior art keywords
cancer
administered
pharmaceutically acceptable
amino
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
KR1020127011758A
Other languages
English (en)
Korean (ko)
Inventor
멜리사 덤블
토나 길머
라케쉬 쿠마르
실비에 라퀴레
피터 에프. 레보위츠
샤논 레내 모리스
Original Assignee
글락소스미스클라인 엘엘씨
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 글락소스미스클라인 엘엘씨 filed Critical 글락소스미스클라인 엘엘씨
Publication of KR20120100978A publication Critical patent/KR20120100978A/ko
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
KR1020127011758A 2009-10-08 2010-10-08 조합물 Abandoned KR20120100978A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US24980309P 2009-10-08 2009-10-08
US61/249,803 2009-10-08

Publications (1)

Publication Number Publication Date
KR20120100978A true KR20120100978A (ko) 2012-09-12

Family

ID=43857162

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020127011758A Abandoned KR20120100978A (ko) 2009-10-08 2010-10-08 조합물

Country Status (16)

Country Link
US (2) US8835450B2 (https=)
EP (1) EP2485593B1 (https=)
JP (1) JP2013507382A (https=)
KR (1) KR20120100978A (https=)
CN (1) CN102665418B (https=)
AU (1) AU2010303363B2 (https=)
BR (1) BR112012008271A2 (https=)
CA (1) CA2777085A1 (https=)
EA (1) EA022982B1 (https=)
ES (1) ES2532026T3 (https=)
IL (1) IL218999A (https=)
MX (1) MX2012004139A (https=)
PL (1) PL2485593T3 (https=)
PT (1) PT2485593E (https=)
WO (1) WO2011044414A1 (https=)
ZA (1) ZA201202494B (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ628394A (en) * 2012-04-24 2016-02-26 Glaxosmithkline Ip No 2 Ltd Treatment method for steroid responsive dermatoses
CN104736154A (zh) * 2012-10-22 2015-06-24 葛兰素史克公司 组合
IN2015DN03909A (https=) * 2012-10-22 2015-10-02 Glaxosmithkline Llc
CN104109159A (zh) 2013-04-17 2014-10-22 杭州普晒医药科技有限公司 苯磺酰胺噻唑化合物的新晶型及其制备方法
CN104540822B (zh) * 2013-07-08 2016-08-31 杭州普晒医药科技有限公司 达拉菲尼甲磺酸盐的晶型及其制备方法

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2349832A1 (en) 1999-01-13 2000-07-20 Warner-Lambert Company Benzenesulfonamide derivatives and their use as mek inhibitors
TR200201364T2 (tr) * 1999-11-22 2002-10-21 Smithkline Beecham P. L. C. Yeni bileşikler.
US20050113423A1 (en) * 2003-03-12 2005-05-26 Vangoor Frederick F. Modulators of ATP-binding cassette transporters
DE102004018198A1 (de) * 2004-04-15 2005-11-03 Merck Patent Gmbh Sulfonamide
AU2005252110B2 (en) * 2004-06-11 2008-09-04 Shionogi & Co., Ltd. 5-amino-2,4,7-trioxo-3,4,7,8-tetrahydro-2H-pyrido[2,3-D] pyrimidine derivatives and related compounds for the treatment of cancer
MY149143A (en) 2006-01-18 2013-07-15 Amgen Inc Thiazole compounds as protien kinase b (pkb) inhibitors
UY30892A1 (es) * 2007-02-07 2008-09-02 Smithkline Beckman Corp Inhibidores de la actividad akt
UA103319C2 (en) * 2008-05-06 2013-10-10 Глаксосмитклайн Ллк Thiazole- and oxazole-benzene sulfonamide compounds

Also Published As

Publication number Publication date
US20140350039A1 (en) 2014-11-27
EP2485593A4 (en) 2013-02-13
US9402846B2 (en) 2016-08-02
EA022982B1 (ru) 2016-04-29
PT2485593E (pt) 2015-04-28
WO2011044414A1 (en) 2011-04-14
EA201270526A1 (ru) 2012-12-28
PL2485593T3 (pl) 2015-06-30
ZA201202494B (en) 2012-12-27
BR112012008271A2 (pt) 2015-09-22
EP2485593B1 (en) 2015-01-07
CN102665418A (zh) 2012-09-12
US8835450B2 (en) 2014-09-16
AU2010303363B2 (en) 2013-09-05
US20120196886A1 (en) 2012-08-02
IL218999A (en) 2015-08-31
CN102665418B (zh) 2014-10-29
CA2777085A1 (en) 2011-04-14
JP2013507382A (ja) 2013-03-04
EP2485593A1 (en) 2012-08-15
MX2012004139A (es) 2012-09-07
AU2010303363A1 (en) 2012-04-26
IL218999A0 (en) 2012-06-28
ES2532026T3 (es) 2015-03-23

Similar Documents

Publication Publication Date Title
US9402846B2 (en) Combination of inhibitor of B-Raf and inhibitor of AKT in the treatment of cancer
US20160213672A1 (en) Combination
KR101696003B1 (ko) 조합물
KR20120099218A (ko) 조합물
US20150094283A1 (en) Combination
US20150272950A1 (en) Combination
JP2013536192A (ja) 組み合わせ
US20150272952A1 (en) Combination

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20120507

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20151007

Comment text: Request for Examination of Application

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20160701

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20160726

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20161117

NORF Unpaid initial registration fee
PC1904 Unpaid initial registration fee